Lucy Sun, MD
Ophthalmology · Fresh Meadows, NYNPI 1245684364
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.
Across 90 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$369
- Mallinckrodt Hospital Products Inc.$296
- AbbVie$242
- Oyster Point Pharma, Inc.$230
- Sun Pharmaceutical Industries Inc.$217
- Biotissue Holdings Inc.$205
- plus $805 from 16 others
What the payments were for
- Food & beverage$2,363100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $369 |
| Mallinckrodt Hospital Products Inc. | 9 | $296 |
| AbbVie | 6 | $242 |
| Oyster Point Pharma, Inc. | 12 | $230 |
| Sun Pharmaceutical Industries Inc. | 10 | $217 |
| Biotissue Holdings Inc. | 5 | $205 |
| Novartis | 6 | $117 |
| Harrow Eye, LLC | 5 | $111 |
| Tarsus Pharmaceuticals, Inc. | 5 | $107 |
| Bausch & Lomb Americas Inc. | 4 | $90 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $74 |
| Amgen(2 entities) | 3 | $60 |
| Ocular Therapeutix, Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $33 |
| Dompe US, Inc. | 1 | $28 |
| Glaukos Corporation | 1 | $26 |
| Sight Sciences, Inc. | 1 | $21 |
| Beaver-visitec International, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,363 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 44 | $58,428 |
| XiidraLifitegrast | 17 | $26,092 |
| ProlensaBromfenac Sodium | 73 | $26,028 |
| LumiganBimatoprost | 40 | $16,334 |
| Prednisolone Acetate | 298 | $8,556 |
| MoxifloxacinMoxifloxacin Hcl | 208 | $4,680 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 69 | $3,476 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,332 |
| Bromfenac Sodium | 12 | $3,023 |
| Latanoprost | 219 | $2,633 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,596 |
| Loteprednol Etabonate | 19 | $2,523 |
| Ketorolac Tromethamine | 74 | $1,307 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 98 | $1,257 |
| Timolol Maleate | 85 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $242 | $74,76284 claims |
| Bausch & Lomb Americas Inc.Xiidra | $90 | $26,09217 claims |
| AlconSimbrinza | $369 | $2,59613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Fresh Meadows
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.